SCHEMBL4717209

SCHEMBL4717209

COC(=O)N(C(CCNC(=O)OC(C)(C)C)C(=O)O)C1c2ccccc2-c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 1/20 0.43
KCNA5 P22460 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
IDO1 P14902 2/20 0.38
PDK2 Q15119 1/20 0.37
TPSAB1 Q15661 2/20 0.37
TPSD1 Q9BZJ3 2/20 0.37
TPSG1 Q9NRR2 2/20 0.37
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
CACNA1G O43497 2/20 0.36
DRD2 P14416 2/20 0.36
BCHE P06276 1/20 0.35
SYK P43405 1/20 0.35
ACE P12821 1/20 0.35
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4612508 1.00 MALT1 (0.43) MALT1KCNA5MEN1GAAKMT2A
SCHEMBL1637220 0.94 KMT2A (0.47) MALT1KCNA5MEN1GAAKMT2A
SCHEMBL4599868 0.94 KMT2A (0.47) MALT1KCNA5MEN1GAAKMT2A
SCHEMBL4600039 0.94 KMT2A (0.47) MALT1KCNA5MEN1GAAKMT2A
SCHEMBL2292771 0.93 TPSAB1 (0.44) MALT1MEN1GAAKMT2ATPSAB1
SCHEMBL4600306 0.93 TPSAB1 (0.44) MALT1MEN1GAAKMT2ATPSAB1
SCHEMBL4599808 0.93 TPSAB1 (0.44) MALT1MEN1GAAKMT2ATPSAB1
SCHEMBL4600478 0.92 TPSAB1 (0.43) MALT1MEN1GAAKMT2ATPSAB1
SCHEMBL4719257 0.91 MALT1 (0.41) MALT1KCNA5MEN1GAAKMT2A
SCHEMBL4599020 0.89 SYK (0.40) MALT1KCNA5MEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537089-A4 COMPOUNDS COMPOSITIONS AND METHODS CYTOKINETICS INC (US) 2008-04-16 EP disclosed
US-20080021050-A1 Compounds, compositions, and methods CYTOKINETICS, INC. 2008-01-24 US disclosed
US-7211580-B2 Compounds, compositions, and methods CYTOKINETICS, INCORPORATED (US) 2007-05-01 US disclosed
EP-1537089-A2 COMPOUNDS COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2005-06-08 EP disclosed
US-20040142949-A1 Compounds, compositions, and methods CYTOKINETICS, INC. 2004-07-22 US disclosed
WO-2004009036-A2 COMPOUNDS COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021050-A1 Compounds, compositions, and methods ALPP, PCNA, MKI67 MALT1 709/4885KCNA5 2933/4885MEN1 1449/4885
US-20040142949-A1 Compounds, compositions, and methods ALPP, PCNA, MKI67 MALT1 709/4885KCNA5 2933/4885MEN1 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.